09926

康方生物

• Reuters·1d ago

  Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's

• PUBT·2d ago

  Akeso says Phase III HARMONi-6 trial shows ivonescimab-chemo cuts death risk 34% in first-line sq-NSCLC

• Reuters·2d ago

  HARMONI-6 DEMONSTRATES SIGNIFICANT OVERALL SURVIVAL BENEFIT (HR=0.66): IVONESCIMAB PLUS CHEMOTHERAPY SUPERIOR TO PD-1 PLUS CHEMOTHERAPY IN FIRST-LINE SQ-NSCLC LANDMARK RESULTS TO BE PRESENTED AT ASCO 2026 PLENARY SESSION

• PUBT·05/26 04:36

  Akeso says Phase 3 HARMONi-6 overall survival data for ivonescimab in first-line squamous NSCLC lands ASCO plenary slot

• Simply Wall St·05/22 05:37

  A Look At Akeso (SEHK:9926) Valuation After New Cadonilimab Approval In Colorectal Cancer

• Simply Wall St·04/30 22:04

  3 Asian Stocks Estimated To Be Up To 31.8% Below Intrinsic Value

• PUBT·04/28 14:33

  TOT Biopharm names Jincai Li chair after Fu resigns

• PUBT·04/28 08:08

  Akeso says Phase III HARMONi-2 trial shows ivonescimab beats pembrolizumab on PFS

• Simply Wall St·04/25 22:09

  Akeso (SEHK:9926) Valuation Check After Positive Cadonilimab Phase II Data In Advanced Pancreatic Cancer

• Simply Wall St·04/22 11:20

  Is It Too Late To Consider Akeso (SEHK:9926) After Strong Five Year Share Gains?

• PUBT·04/21 02:54

  Akeso says cadonilimab-chemo extends OS past 23 months in phase 2 pancreatic cancer trial

• Simply Wall St·04/13 11:16

  Assessing Akeso (SEHK:9926) Valuation After Positive Lung Cancer Data At 2026 European Lung Cancer Congress

• Reuters·04/07 03:29

  Akeso says cadonilimab combo posts 7-month median PFS in resistant NSCLC study

• Simply Wall St·04/06 02:17

  Akeso (SEHK:9926) Valuation Check After New HARMONi-2 Quality Of Life And Survival Data

• Reuters·03/31 20:40

  Akeso says ivonescimab improves quality of life vs pembrolizumab in Phase III NSCLC study